A Non-Randomized, Open-Label, Dose-Finding, First-in-human Trial of Combined Cytotoxic and Immune-Stimulatory Gene Therapy for Primary Adult High-Grade Glioma: Transgene Expression Persists Up to 17 Months Post-Vector Injection